-
Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa437.
Gandelman JS, Kim EY, Grzegorczyk AM, Zejnullahu K, Edson RS. PMID: 33094121.
View in:
PubMed Mentions:
-
Off Trail, On Track: an Exercise in Clinical Reasoning. J Gen Intern Med. 2019 10; 34(10):2282-2287.
Zejnullahu K, Santhosh L, Mourad M, Connor DM. PMID: 31270781.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1.
Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
View in:
PubMed Mentions:
1 Fields:
Translation:
HumansCTClinical Trials
-
Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e23055-e23055.
Anantharaman AA, Friedlander FT, Welty WC, Zejnullahu ZK, Hough HJ, Edwards EM, Jendrisak JA, Lee LJ, Greene GS, Ontiveros OP, Graf GR, Rodriguez RA, Suraneni SM, Wang WY, Landers LM, Cooperberg CM, Carroll CP, Dittamore DR, Paris PP. .
View in:
Publisher Site Mentions:
-
Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 Feb 20; 35(6_suppl):110-110.
Friedlander FT, Anantharaman AA, Welty WC, Zejnullahu ZK, Hough HJ, Edwards EM, Jendrisak JA, Lee LJ, Greene GS, Ontiveros OP, Graf GR, Rodriguez RA, Suraneni SM, Wang WY, Landers LM, Cooperberg CM, Carroll CP, Dittamore DR, Paris PP. .
View in:
Publisher Site Mentions:
-
Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 08; 34(8):368-74.
Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R, Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. PMID: 26944450.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears. J Gen Intern Med. 2016 07; 31(7):812-3.
Zejnullahu K, Khatami S, Manesh RS, Zejnullahu K, Khatami S, Manesh RS. PMID: 26892322; PMCID: PMC4907939.
View in:
PubMed Mentions: Fields:
Translation:
Humans
-
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife. 2015 Jun 05; 4:e06907.
Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H, Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H. PMID: 26047463; PMCID: PMC4478584.
View in:
PubMed Mentions:
55 Fields:
Translation:
HumansAnimalsCells
-
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013 Jan 15; 73(2):834-43.
Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA, Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA. PMID: 23172312; PMCID: PMC3994895.
View in:
PubMed Mentions:
84 Fields:
Translation:
HumansCells
-
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19408-13.
Lockwood WW, Zejnullahu K, Bradner JE, Varmus H, Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. PMID: 23129625; PMCID: PMC3511085.
View in:
PubMed Mentions:
161 Fields:
Translation:
HumansCells
-
OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. European Journal of Cancer. 2011 Oct 1; 47:s10.
Yonesaka YK, Zejnullahu ZK, Okamoto OI, Satoh ST, Cappuzzo CF, Souglakos SJ, Engelman EJ, Varella-Garcia VM, Nakagawa NK, Jänne JP. .
View in:
Publisher Site Mentions:
-
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011 Sep 07; 3(99):99ra86.
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA, Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. PMID: 21900593; PMCID: PMC3268675.
View in:
PubMed Mentions:
235 Fields:
Translation:
HumansAnimalsCells
-
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010 Apr 22; 29(16):2346-56.
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA, Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. PMID: 20118985; PMCID: PMC2859699.
View in:
PubMed Mentions:
92 Fields:
Translation:
HumansCells
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88.
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA, Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. PMID: 20129249; PMCID: PMC2980857.
View in:
PubMed Mentions:
436 Fields:
Translation:
HumansAnimalsCells
-
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73.
Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA, Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA. PMID: 18980991; PMCID: PMC3227691.
View in:
PubMed Mentions:
63 Fields:
Translation:
HumansCells
-
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 01; 14(13):4275-83.
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA, Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. PMID: 18594010; PMCID: PMC3025451.
View in:
PubMed Mentions:
335 Fields:
Translation:
HumansCells
-
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32.
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA, Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PMID: 18089823.
View in:
PubMed Mentions:
239 Fields:
Translation:
HumansAnimalsCells
-
C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s361.
Park PJ, Zhao ZF, Zejnullahu ZK, Normant NE, Engelman EJ, Johnson JB, Jänne JP. .
View in:
Publisher Site Mentions:
-
D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s396.
Engelman EJ, Zejnullahu ZK, Mitsudomi MT, Hyland HC, Park PJ, Lindeman LN, Gale GC, Zhao ZX, Christensen CJ, Rogers RR, Cappuzzo CF, Mok MT, Lee LC, Bruce BJ, Cantley CL, Jänne JP. .
View in:
Publisher Site Mentions:
-
C7-07: Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s382.
Yonesaka YK, Zejnullahu ZK, Homes HA, Johnson JB, Janne JP. .
View in:
Publisher Site Mentions:
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA, Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. PMID: 17463250.
View in:
PubMed Mentions:
1825 Fields:
Translation:
HumansAnimalsCells
-
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA, Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. PMID: 16906227; PMCID: PMC1570180.
View in:
PubMed Mentions:
202 Fields:
Translation:
HumansAnimalsCells